Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProStrakan Group, a specialty pharmaceutical company, has signed an exclusive licensing and supply agreement with UAE-based NewBridge Pharmaceuticals for Sancuso, ProStrakan's novel, patent protected transdermal patch for the prevention of chemotherapy-induced nausea and vomiting, for the Middle East and Africa.
Subscribe to our email newsletter
Under the terms of the agreement, covering 59 countries across the Middle East and Africa, ProStrakan will receive undisclosed upfront and milestone payments, subject to the achievement of certain approvals and sales targets. NewBridge will be required to purchase Sancuso directly from ProStrakan at a pre-agreed price.
Sancuso is a transdermal patch that delivers granisetron, an established 5HT3 receptor antagonist, steadily into the bloodstream for up to seven days. Sancuso has been shown to be as effective as oral granisetron in preventing the side effects of nausea and vomiting in patients undergoing chemotherapy.
Wilson Totten, ProStrakan’s CEO, said: “While ProStrakan’s core markets are Europe and the US, we continue to seek out opportunities to create a revenue stream from our products in territories that are non-core, yet likely to be lucrative, for us.
“Our partnership with NewBridge will potentially allow Sancuso to be made available for millions of cancer patients across the Middle East and Africa in order that they too may be relieved of the often distressing effects of chemotherapy-induced nausea and vomiting.”